human
coronaviru
infect
caus
acut
respiratori
distress
syndrom
ard
hypercoagul
hypertens
extrapulmonari
multiorgan
dysfunct
effect
antivir
anticoagul
agent
safe
clinic
profil
urgent
need
improv
overal
prognosi
screen
fda
approv
drug
librari
found
anticoagul
agent
dipyridamol
dip
suppress
replic
nm
vitro
also
elicit
potent
type
interferon
respons
amelior
lung
patholog
viral
pneumonia
model
analysi
twelv
infect
patient
prophylact
anticoagul
therapi
found
dip
supplement
associ
significantli
increas
platelet
lymphocyt
count
decreas
ddimer
level
comparison
control
patient
two
week
initi
dip
treatment
sever
case
mild
case
discharg
hospit
one
critic
ill
patient
extrem
high
level
ddimer
lymphopenia
time
receiv
dip
pass
away
patient
clinic
remiss
summari
infect
patient
could
potenti
benefit
dip
adjunct
therapi
reduc
viral
replic
suppress
hypercoagul
enhanc
immun
recoveri
larger
scale
clinic
trial
dip
need
valid
therapeut
effect
countri
japan
south
korea
itali
singapor
iran
thailand
usa
rapid
spread
threaten
becom
pandem
date
agent
report
effect
viral
entri
host
cell
coronaviru
messeng
rna
first
translat
yield
polyprotein
subsequ
cleav
two
viral
proteinas
proteas
aka
mpro
papainlik
proteas
plp
yield
nonstructur
protein
essenti
viral
replic
inhibitor
suppress
activ
proteas
may
inhibit
viral
replic
offer
revenu
therapi
inflamm
promot
mucos
heal
third
panpd
inhibitor
dip
may
prevent
acut
injuri
progress
fibrosi
lung
heart
liver
kidney
provid
three
level
evid
advoc
dip
therapi
silico
vitro
demonstr
dip
possess
effect
vsvinduc
pneumonia
model
also
confirm
dip
elicit
potent
antivir
immun
significantli
improv
surviv
rate
small
clinic
cohort
found
dip
adjunct
therapi
led
increas
circul
lymphocyt
platelet
count
lower
ddimer
level
markedli
improv
clinic
outcom
free
energi
perturb
surfac
plasmon
reson
spr
assay
virtual
screen
fdaapprov
drug
databas
use
proteas
mpro
target
valid
bind
affin
spr
assay
dip
pubchem
cid
figur
identifi
lead
drug
order
obtain
bind
pattern
calcul
bind
free
energi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
dip
mpro
dip
firstli
dock
onto
mpro
use
glide
optim
bind
pose
assess
absolut
bind
free
energi
calcul
free
energi
perturb
calcul
carri
gromac
thermodynam
cycl
procedur
similar
use
matteo
et
al
calcul
ligand
electrostat
van
der
waal
interact
decoupl
use
linear
alchem
pathway
van
der
waal
electrostat
interact
add
restraint
valu
use
therefor
total
window
complex
window
ligand
system
employ
plasmid
construct
atagenix
wuhan
transfect
e
coli
strain
codonplu
stratagen
gsttag
protein
purifi
gstglutathion
affin
chromatographi
cleav
fxa
puriti
recombin
protein
greater
judg
sdspage
bind
dip
mpro
measur
biacor
system
ge
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
min
respons
unit
follow
block
step
use
ethanolamin
ph
min
bind
studi
perform
pass
dip
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
studi
variabl
februari
confirm
case
identifi
zhongnan
hospit
wuhan
univers
tabl
patient
met
diagnost
criteria
diagnosi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
virtual
screen
fda
approv
drug
librari
found
dip
bound
proteas
mpro
figur
hydrophob
hydrogen
bond
hbond
interact
main
drive
forc
bind
dip
mpro
accord
free
energi
perturb
calcul
bind
free
energi
kcalmol
spr
assay
carri
valid
silico
result
reveal
dip
bound
mpro
experiment
confirm
affin
kd
eq
figur
demonstr
directli
dip
suppress
replic
measur
viral
titer
use
publish
studi
shown
dip
possess
broad
spectrum
activ
wide
rang
virus
indic
may
elicit
antivir
immun
host
cell
examin
use
two
tabl
baselin
temperatur
higher
oxygen
statu
wors
diptreat
group
control
group
howev
temperatur
oxygen
stabil
mild
sever
patient
group
one
day
treatment
figur
furthermor
observ
continu
increas
trend
lymphocyt
count
significantli
increas
platelet
tabl
measur
dynam
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
chang
refer
respect
baselin
level
patient
found
level
ddimer
continu
rose
control
group
wherea
decreas
stabil
diptreat
group
figur
figur
examin
two
critic
ill
patient
receiv
dip
adjunct
therapi
man
low
oxygen
satur
suffer
hypoxia
multiorgan
dysfunct
patient
chest
ct
scan
show
typic
multipl
patchi
groundglass
shadow
lung
treatment
dip
treat
patient
lesion
vari
degre
absorpt
typic
find
follow
dip
treatment
illustr
one
sever
patient
taken
sequenti
ct
scan
figur
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
china
lancet
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
experi
p
valu
calcul
student
test
p
p
p
p
data
f
present
mice
per
group
p
valu
calcul
logrank
mantelcox
test
conserv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
lymphocyt
count
persist
elev
trend
plt
count
significantli
increas
dip
group
comparison
control
group
data
shown
mean
se
across
differ
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
